Biofrontera (BFRI) Gross Margin (2020 - 2025)

Biofrontera's Gross Margin history runs 6 years deep, the most recent figure standing at 82.4% for Q4 2025.

• On a quarterly basis, Gross Margin rose 2437.0% year-over-year to 82.4% in Q4 2025; TTM through Dec 2025 was 73.71%, a 2356.0% increase from a year earlier, with the FY2025 full-year figure at 73.71%, up 2357.0% from the prior year.
• Gross Margin advanced to 82.4% in Q4 2025 per BFRI's latest filing, from 70.74% in the prior quarter.
• Across five years, Gross Margin topped out at 112.8% in Q4 2023 and bottomed at 72.27% in Q4 2022.
• The 5-year median for Gross Margin is 76.57% (2025), against an average of 70.47%.
• Across the five-year window, Gross Margin slumped 17349 bps in 2022 and soared 18507 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 101.22% in 2021, then sank by 171 bps to 72.27% in 2022, then surged by 256 bps to 112.8% in 2023, then tumbled by 49 bps to 58.03% in 2024, then jumped by 42 bps to 82.4% in 2025.
• Per Business Quant, the three latest BFRI Gross Margin figures stand at 82.4% (Q4 2025), 70.74% (Q3 2025), and 70.74% (Q2 2025).